High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due to upcoming patent expiries are key factors contributing to high CAGR of Idiopathic Thrombocytopenic Purpura Therapeutics during forecast period.
Market Size – USD 498 Million in 2018, Market Growth – CAGR of 5.8%, Market Trends – Product launches and research for advanced Idiopathic Thrombocytopenic Purpura Therapeutics.
According to the current analysis of Reports and Data, the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market was valued at USD 498 Million in 2018 and is expected to reach USD 783 Million by year 2026, at a CAGR of 5.8 %. The study covers therapeutic agents for ‘Idiopathic thrombocytopenic purpura’ – Idiopathic thrombocytopenic purpura is a hematologic disorder, caused due to abnormal decrease in the platelet count. It is clinically diagnosed as acquired bleeding disorder in which platelets (blood cells), who play a vital role in primary and secondary haemostasis are destroyed by immune system. Rising prevalence of target diseases, unmet needs of Idiopathic thrombocytopenic purpura patients pushing the drug development, significant focus of pharmaceutical companies on development of novel mechanisms based Idiopathic thrombocytopenic purpura drugs, upcoming patent expiry, availability of public as well private funds for research, and favorable regulatory scenario, are some of the key factors propelling market growth in the industry. However, associated side effects, and lack of awareness of disease, are the major hindrance for market growth during 2019 – 2026.
Furthermore, the report is furnished with the latest impact of the COVID-19 pandemic on the market. The pandemic has affected every segment of the market, along with bringing disruption in the supply chain, demands & trends, and financial difficulties. The report covers the initial and future assessment of the COVID-19 impact on the market.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2197
The report covers the market dynamics analysis, company profiles, production and manufacturing capacity, product specifications, product value, and key players. The report also offers an insight into the growth prospects during the forecast period. The Idiopathic Thrombocytopenic Purpura (ITP) Market report also offers detailed data on the key market players to impart a deeper understanding of the competitive landscape. The report focuses on the key market elements to ensure the readers gain a competitive advantage and maximum benefit of the market data to assist them in achieving substantial growth and an advantageous position in the global market.
Key findings of the report:
Idiopathic Thrombocytopenic Purpura Therapeutics market is growing at a CAGR of 3 % in North America followed by Asia Pacific and Europe, respectively. High disease prevalence across the globe is the prominent factor to accelerate the market growth during the forecast period across all regions
As of 2018, Product type segment, Corticosteroids is the dominating Idiopathic Thrombocytopenic Purpura Therapeutics which holds 35.5 % of the global market. European regional market is the prominent revenue generating source for this product segment, followed by North America, Asia-Pacific, and other regions
Anti-D immunoglobulin product type segment is expected to be the fastest growing market segment during the forecast period 2019 – 2026 with a CAGR of 6.6 %. However, associated side effects and high costs are major restraints for the market growth of this market segment
Retail pharmacies distribution channels type segment was growing at an appreciable CAGR during the forecast period
Asia Pacific is expected to account for the 19.2 % of the global Idiopathic Thrombocytopenic Purpura Therapeutics market. Developing nations such China, and India are likely to witness high growth owing it to growing awareness about the disease and untapped market potential
Europe regional segment is anticipated to witness significant growth during the forecast period 2019 – 2026. The regional segment was valued at second highest in the year 2018, and is expected to reach upwards of USD 200 million by the year 2026
Associated side effects related to Idiopathic Thrombocytopenic Purpura Therapeutics and lack of awareness about pruritus is likely to hinder the market growth during the forecast period
Key participants include Hoffman-L Roche, Novartis, GlaxoSmithKline, Eisai, Amgen, Grifols Biologicals Inc., Baxter, CSL Behring, Bristol-Myers Squibb, Roxane, and others.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2197
For the purpose of this study, the global Idiopathic Thrombocytopenic Purpura (ITP) market has been segmented on the basis of disease type, application, distribution channel, and region:
Product Type of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue, USD Million; 2016–2026)
- Corticosteroids
- Intravenous immunoglobulins
- Anti-D immunoglobulin
- Thrombopoietin receptor agonists (TPO-RA)
- Others
Distribution channels Type of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue, USD Million; 2016–2026)
- Drug store
- Retail pharmacies
- Others
Treatment Type of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue, USD Million; 2016–2026)
- Oral corticosteroids
- Spleenectomy
By Region (Revenue, USD Million; 2017-2027)
North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- BENELUX
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- U.A.E.
- Rest of Middle East & Africa
Key Coverage of the Report:
- An in-depth analysis of the historical years and the forecast period has been offered in the report
- Idiopathic Thrombocytopenic Purpura (ITP) Market dynamics, including key drivers, challenges, restraints, threats, and growth opportunities have been analyzed in reports
- SWOT analysis and Porter’s Five Forces analysis with feasibility analysis and investment return analysis
- Competitive landscape benchmarking along with a comprehensive overview of their company profiles, product portfolios, strategic business decisions, and financial standings
- The report covers mergers and acquisitions, product launches and brand promotions, joint ventures, collaborations, and partnerships among few
- Pictorial representation of the key statistical data into graphs, tables, charts, diagrams, and figures
- An in-depth analysis of the current and emerging market trends and developmental patterns
Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2197
Thank you for reading our report. To know more about customization options, please get in touch with us. Our team will ensure the report is tailored to suit your requirements.
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States
Website: https://www.reportsanddata.com/report-detail/idiopathic-thrombocytopenic-purpura-itp-therapeutics-market